Kapur, S., Silverman, A. P., Ye, A. Z., Papo, N., Jindal, D., Blumenkranz, M. S., & Cochran, J. R. (2017). Engineered ligand‐based VEGFR antagonists with increased receptor binding affinity more effectively inhibit angiogenesis. Bioeng Transl Med.

Kapur, Shiven, Adam P. Silverman, Anne Z. Ye, Niv Papo, Darren Jindal, Mark S. Blumenkranz, et Jennifer R. Cochran. "Engineered Ligand‐based VEGFR Antagonists With Increased Receptor Binding Affinity More Effectively Inhibit Angiogenesis." Bioeng Transl Med 2017.

Kapur, Shiven, et al. "Engineered Ligand‐based VEGFR Antagonists With Increased Receptor Binding Affinity More Effectively Inhibit Angiogenesis." Bioeng Transl Med 2017.